Immunic, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
IMUX Nasdaq 2836 imux.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Immunic, Inc.

Immunic presents new vidofludimus calcium data at multiple sclerosis conference - May 28th, 2026 8:29 am
Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the CMSC Annual Meeting 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis - May 28th, 2026 4:30 am
Immunic names Erik Lundgren as CEO as it advances Phase 3 MS trials - May 27th, 2026 7:06 am
Immunic Appoints Distinguished Biopharmaceutical Executive Erik Lundgren as Chief Executive Officer - May 27th, 2026 4:30 am
EXCLUSIVE: Immunic Appoints Former Genentech Exec Erik Lundgren As CEO - May 27th, 2026 4:17 am
Immunic appoints Biogen, Cubist veteran Mike Bonney as board chair ahead of key MS trial readout - May 19th, 2026 7:33 am
Immunic Appoints Seasoned Biopharmaceutical Executive Michael W. Bonney as Chair of the Board of Directors - May 19th, 2026 4:30 am
Is Immunic (NASDAQ:IMUX) In A Good Position To Deliver On Growth Plans? - May 17th, 2026 8:31 am
Immunic advances Phase 3 MS program, eyes topline data by year-end - May 13th, 2026 7:04 am
Immunic, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate Update - May 13th, 2026 4:30 am
Immunic CEO on Q1 highlights, new appointments and upcoming milestones - May 7th, 2026 6:47 am
Immunic to Participate in Investor and Medical Conferences in May - Apr 30th, 2026 4:30 am
Immunic appoints Michael Panzara as CMO ahead of pivotal MS drug readout - Apr 28th, 2026 6:40 am
Immunic Appoints Accomplished Biopharmaceutical Executive Michael A. Panzara, M.D., M.P.H., as Chief Medical Officer - Apr 28th, 2026 4:30 am
Immunic to implement 1-for-10 reverse stock split - Apr 23rd, 2026 6:52 am
Immunic, Inc. Announces 1-for-10 Reverse Stock Split - Apr 23rd, 2026 6:00 am
Immunic to Participate in Scientific and Medical Conferences in April - Apr 9th, 2026 4:30 am
Immunic COO highlights the importance of science-led innovation to mark World Health Day - Apr 7th, 2026 6:05 am
Immunic Regains Compliance with Nasdaq Minimum Bid Price Requirement - Apr 1st, 2026 4:30 am
Immunic appoints biopharmaceutical executive Jon Congleton to board - Mar 31st, 2026 8:17 am